160 related articles for article (PubMed ID: 8990627)
1. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Zama T; Murata M; Ono F; Watanabe K; Watanabe R; Moriki T; Yokoyama K; Tokuhira M; Ikeda Y
Int J Hematol; 1996 Dec; 65(1):71-8. PubMed ID: 8990627
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
[TBL] [Abstract][Full Text] [Related]
3. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene.
Chan LC; Bourke C; Lam CK; Liu HW; Brookes S; Jenkins V; Pasi J
Thromb Haemost; 1996 Mar; 75(3):522-3. PubMed ID: 8701422
[No Abstract] [Full Text] [Related]
4. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Williamson D; Brown K; Luddington R; Baglin C; Baglin T
Blood; 1998 Feb; 91(4):1140-4. PubMed ID: 9454742
[TBL] [Abstract][Full Text] [Related]
5. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
6. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Zöller B; Svensson PJ; He X; Dahlbäck B
J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
[TBL] [Abstract][Full Text] [Related]
7. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
De Lucia D; Papa ML; Ammendola F; Pezzella S; Del Giudice V; Marotta R; Renis V; Di Mauro C; Maisto G; Masi S; Nina P; Franco A; Schisano G
J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Fisher M; Fernandez JA; Ameriso SF; Xie D; Gruber A; Paganini-Hill A; Griffin JH
Stroke; 1996 Jul; 27(7):1163-6. PubMed ID: 8685921
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations.
Kodaira H; Ishida F; Shimodaira S; Takamiya O; Furihata K; Kitano K
Acta Haematol; 1997; 98(1):22-5. PubMed ID: 9210909
[TBL] [Abstract][Full Text] [Related]
10. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
11. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.
Voorberg J; Roelse J; Koopman R; Büller H; Berends F; ten Cate JW; Mertens K; van Mourik JA
Lancet; 1994 Jun; 343(8912):1535-6. PubMed ID: 7911872
[TBL] [Abstract][Full Text] [Related]
12. Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Ma DD; Aboud MR; Williams BG; Isbister JP
Aust N Z J Med; 1995 Apr; 25(2):151-4. PubMed ID: 7605298
[TBL] [Abstract][Full Text] [Related]
13. Arterial and venous thrombosis in two Italian families with the factor V Arg506-->Gln mutation.
Montaruli B; Voorberg J; Tamponi G; Borchiellini A; Muleo G; Pannocchia A; van Mourik JA; Schinco P
Eur J Haematol; 1996 Jul; 57(1):96-100. PubMed ID: 8698138
[TBL] [Abstract][Full Text] [Related]
14. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
Svensson PJ; Zöller B; Mattiasson I; Dahlbäck B
J Intern Med; 1997 May; 241(5):379-85. PubMed ID: 9183305
[TBL] [Abstract][Full Text] [Related]
15. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
16. [Activated protein C resistance: role in venous and arterial thrombosis].
Emmerich J; Alhenc-Gelas M; Aiach M; Fiessinger JN
Arch Mal Coeur Vaiss; 1996 Jun; 89(6):741-5. PubMed ID: 8760661
[TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Dahlbck B
J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
19. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
Bernardi F; Faioni EM; Castoldi E; Lunghi B; Castaman G; Sacchi E; Mannucci PM
Blood; 1997 Aug; 90(4):1552-7. PubMed ID: 9269773
[TBL] [Abstract][Full Text] [Related]
20. The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients.
Leroy-Matheron C; Levent M; Pignon JM; Mendonça C; Gouault-Heilmann M
Thromb Haemost; 1996 Jan; 75(1):4-10. PubMed ID: 8713771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
